RESEARCHER PROFILE
Professor Kristofer Thurecht, Deputy Director of Research & Senior
Group leader, Australian Institute for Bioengineering and Nanotechnology,
University of Queensland, Australia
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
Professor Thurecht undertook his PhD at the University of Queensland and decided he wanted to go to the University of Nottingham in the UK, where his mentors pushed him into the new field of nanomedicine. On returning to Australia he brought his ideas on nanomedicine back to the University of Queensland, where he works today.
His research focuses on understanding how nanomedicines behave in biological environments using high-end imaging infrastructure, with a focus on radiopharmaceutical research to establish next generation drugs for diseases like cancer.
Nanomedicine research, particularly in the field of cancer treatment, has the potential to revolutionise traditional medicine and improve the quality of life for those suffering from the disease. Radiopharmaceuticals and molecular imaging are revolutionising cancer treatment by providing targeted therapies and precise drug delivery, showing potential for groundbreaking advancements in the field.
Radiopharmaceuticals utilise radiation as a potent therapy for treating diseases, particularly cancer. As Professor Thurecht states, the development of radiopharmaceutical for cancer treatment is a promising and innovative field in nanomedicine.
Outside of research Professor Thurecht enjoys fishing and boating with family on weekends.
You Might also like
-
Therapies for chronic myeloid leukaemia
Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
-
Biostatistics in Clinical Trials
As a biostatistician working in research and clinical settings, Kate Francis plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
-
Antimicrobial technologies & drug delivery platforms
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.